ArticleJournal of anesthesia and translational medicine2026
Association between the EU desflurane phase-out and secondary market vaporizer prices: An observational time-series analysis.
Article in Journal of anesthesia and translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The European Union restricted desflurane-the volatile anesthetic with the highest commonly reported 100-year global warming potential (GWP100 ≈ 2540 CO₂ equivalents)-for routine use from 1 January 2026 under Regulation (EU) 2024/573, with exemptions for clinically necessary cases. Whether this targeted environmental regulation was associated with collateral economic effects on non-targeted anesthetic equipment markets has not been examined. We investigated whether the EU desflurane regulation was associated with changes in secondary market prices of anesthetic vaporizers, and whether any such changes were agent-specific or extended to non-regulated agents (sevoflurane, isoflurane). Methods: We conducted a cross-sectional time-series analysis of completed eBay sales of desflurane, sevoflurane, and isoflurane vaporizers over three years (March 2023 to March 2026), spanning the full EU regulatory timeline. Temporal trends were assessed using Spearman rank correlation and Kendall τ across ordered regulatory phases. Pre-/post-ban comparison used the Mann-Whitney U test with Cohen's d effect size. Sensitivity analyses included bootstrap resampling (10,000 iterations), post-hoc power simulation under observed lognormal parameters, and a comparative interrupted time-series (CITS) model of monthly median prices with sevoflurane and isoflurane as controls. Results: 1033 completed sales were analyzed (158 desflurane, 321 sevoflurane, 554 isoflurane). Desflurane vaporizer prices declined (Spearman ρ = -0.28, Conclusions: Desflurane vaporizer prices on eBay were associated with an agent-specific decline; non-regulated agents remained comparatively stable. These observational findings are consistent with, but do not establish, an effect of the EU desflurane phase-out and should be interpreted as hypothesis-generating, given the single-platform design, unmeasured confounders, small post-restriction sample size, and multiple trend tests.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.